News

40% Upside For Merck Stock?
MK-0616, an experimental oral medication aimed at reducing LDL cholesterol, is intended to be the first oral PCSK9 inhibitor.
New CDC vaccine advisers endorse thimerosal-free flu vaccines, despite no evidence of harm from the preservative
A new slate of vaccine advisers to the US Centers for Disease Control and Prevention voted Thursday to recommend that ...
2 Stocks Too Cheap to Ignore at These Prices
It boasts more than 80 programs in phase 2 or phase 3 studies. Even with a 25% success rate for these, that should translate ...
GEN - Genetic Engineering and Biotechnology News1d
Solution Building: Merck Avoids One-Size-Fits-All Approach to AI and ML
Iya Khalil, PhD, discusses Merck & Co.’s approach to artificial intelligence (AI), and success in applying the technology, ...
Merck Poised to Deliver Strong Results and Steady Dividend Growth
The company has raised its payouts for 14 consecutive years, and its nearly 89% growth over the last 10 years provides a ...
Merck & Co. Inc. stock outperforms competitors on strong trading day
Merck & Co. Inc. closed 40.46% short of its 52-week high of $134.63, which the company reached on June 25th.
Merck exec says Chernobyl changed the course of her life after her father begged her to leave nuclear physics on his deathbed
Gen Z grads are slamming degrees as worthless—but Fortune 500 boss, Doina Ionescu, says her MBA was the best investment ...
Merck succeeds in late-stage study of PAH treatment
Merck (NYSE:MRK) said on Monday that its late-stage study, testing Winrevair in adults with moderate to high risk pulmonary ...
Merck's Pulmonary Arterial Hypertension Drug Meets Primary Endpoint
Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints.